OSI-906

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Adrenocortical Carcinoma

Conditions

Adrenocortical Carcinoma

Trial Timeline

Dec 1, 2009 → Oct 8, 2012

NCT ID

NCT00924989

About OSI-906

OSI-906 is a phase 3 stage product being developed by Astellas Pharma for Adrenocortical Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00924989. Target conditions include Adrenocortical Carcinoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00924989	Phase 3	Completed	Dec 1, 2009	Oct 8, 2012	Adrenocortical Carcinoma
NCT00514306	Phase 1	Completed	Jul 5, 2007	Sep 20, 2010	Advanced Solid Tumors
NCT00514007	Phase 1	Completed	Jun 18, 2007	Mar 19, 2012	Advanced Solid Tumors

Competing Products

6 competing products in Adrenocortical Carcinoma

See all competitors

Product	Company	Stage	Hype Score
DS9051b	Daiichi Sankyo	Phase 1	36
Iressa (ZD1839)	AstraZeneca	Phase 2	35
Pembrolizumab	Merck	Phase 2	39
BGG492	Novartis	Phase 2	35
Sunitinib	Pfizer	Phase 2	35
Relacorilant + Pembrolizumab	Corcept Therapeutics	Phase 1	26